Esaxerenone: First Global Approval

被引：68

作者：

Duggan, Sean ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2019年 / 79卷 / 04期

关键词：

MINERALOCORTICOID RECEPTOR ANTAGONIST; CS-3150; HYPERTENSION; INJURY;

D O I：

10.1007/s40265-019-01073-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Esaxerenone (MINNEBRO (TM))-a novel oral, non-steroidal, selective mineralocorticoid receptor blocker-is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.

引用

页码：477 / 481

页数：5

共 10 条

[1] CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats [J].

Arai, Kiyoshi ;

Morikawa, Yuka ;

Ubukata, Naoko ;

Tsuruoka, Hiroyuki ;

Homma, Tsuyoshi .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 358 (03) :548-557

[2] CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats [J].

Arai, Kiyoshi ;

Tsuruoka, Hiroyuki ;

Homma, Tsuyoshi .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 769 :266-273

[3] Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist [J].

Arai, Kiyoshi ;

Homma, Tsuyoshi ;

Morikawa, Yuka ;

Ubukata, Naoko ;

Tsuruoka, Hiyoyuki ;

Aoki, Kazumasa ;

Ishikawa, Hirokazu ;

Mizuno, Makoto ;

Sada, Toshio .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 761 :226-234

[4]

Daiichi Sankyo, 2019, ESAXERENONE MINNEBRO

[5] TREATMENT WITH ESAXERENONE (CS-3150) IS ASSOCIATED WITH A SIGNIFICANT DOSE-DEPENDENT ANTIHYPERTENSIVE EFFECT IN ESSENTIAL HYPERTENSIVE PATIENTS [J].

Ito, S. ;

Ito, H. ;

Rakugi, H. ;

Okuda, Y. ;

Yamakawa, S. .

JOURNAL OF HYPERTENSION, 2017, 35 :E173-E173

[6] A DOUBLE BLIND PHASE III STUDY OF ESAXERENONE (CS-3150) COMPARED TO EPLERENONE IN PATIENTS WITH ESSENTIAL HYPERTENSION (ESAX-HTN STUDY) [J].

Ito, S. ;

Ito, H. ;

Rakugi, H. ;

Okuda, Y. ;

Yoshimura, M. ;

Yamakawa, S. .

JOURNAL OF HYPERTENSION, 2018, 36 :E239-E239

[7] Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects [J].

Kato, Manabu ;

Furuie, Hidetoshi ;

Shimizu, Takako ;

Miyazaki, Atsuhiro ;

Kobayashi, Fumiaki ;

Ishizuka, Hitoshi .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (08) :1821-1829

[8]

Mulatero Paolo, 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P75, DOI 10.2174/187152506775268776

[9] Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension [J].

Shibata, Shigeru ;

Ishizawa, Kenichi ;

Uchida, Shunya .

HYPERTENSION RESEARCH, 2017, 40 (03) :221-225

[10] Pharmacokinetics, Metabolism, and Excretion of [14C] Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans [J].

Yamada, Makiko ;

Mendell, Jeanne ;

Takakusa, Hideo ;

Shimizu, Takako ;

Ando, Osamu .

DRUG METABOLISM AND DISPOSITION, 2019, 47 (03) :340-349

← 1 →